The WACC of Immunoprecise Antibodies Ltd (IPA.V) is 6.9%.
| Range | Selected | |
| Cost of equity | 5.40% - 8.40% | 6.90% |
| Tax rate | 1.90% - 3.90% | 2.90% |
| Cost of debt | 7.00% - 7.00% | 7.00% |
| WACC | 5.5% - 8.4% | 6.9% |
| Category | Low | High |
| Long-term bond rate | 2.6% | 3.1% |
| Equity market risk premium | 4.7% | 5.7% |
| Adjusted beta | 0.61 | 0.85 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 5.40% | 8.40% |
| Tax rate | 1.90% | 3.90% |
| Debt/Equity ratio | 0.02 | 0.02 |
| Cost of debt | 7.00% | 7.00% |
| After-tax WACC | 5.5% | 8.4% |
| Selected WACC | 6.9% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for IPA.V:
cost_of_equity (6.90%) = risk_free_rate (2.85%) + equity_risk_premium (5.20%) * adjusted_beta (0.61) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.